A study was published in the "New England Journal of Medicine" on October 8 indicating that scientists confirmed the potency of remdesivir as COVID-19 treatment for hospitalized patients.
What is Remdesivir?
Remdesivir is an antiviral drug that has acquired emergency use authorization (EUA) from the United. Food and Drug Administration (FDA) for the treatment of patients who tested positive for the illness.
Numerous therapeutic agents have been assessed for the treatment of coronavirus disease 2019. However, no antiviral agents have yet shown to be effective.
United States President Donald Trump also took Gilead's remdesivir. Gilead's antiviral drug has shortened recovery duration for the novel coronavirus patients in early research, reported KHN.
After the publication of peer-reviewed information from remdesivir's large-scale trial, feedback came and it was confirmed that the antiviral drug aided coronavirus patients admitted to the hospital recuperate 5 days more swiftly. For ailing patients with severe symptoms who took remdesivir, recovery was expedited by seven days.
Global Supply of Remdesivir
According to CEO Daniel O'Day, Gilead Sciences would provide the supply of its COVID-19 treatment remdesivir across the globe by October's end.
"These results are meaningful. They'll definitely help patients around the world who have the misfortune of entering into the hospital to get better, and I'm really pleased to say that we have ample supply," said O'Day, reported CNBC.
Acute Kidney Injury?
However, according to the European Medicines Agency (EMA) that has begun a review to evaluate reports of acute kidney injury in a number of COVID-19 patients being administered remdesivir, "At this stage, it has not been determined whether there is a causal relationship between Veklury and the reports of acute kidney injury. The reports form a 'safety signal'-information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation," reported TCT MD.
Remdesivir Publicly Available
The United States Department of Health and Human Services (HHS) recently made an announcement that remdesivir, which is currently authorizes for emergency use for adult and pediatric patients with confirmed or supposed COVID-19, is now accessible directly from its drug maker company.
For the previous five months, the federal government has been supervising the allocation and dissemination of the drug being probed into.
In 2018, it was an antiviral created to combat the Ebola virus. However, it did not fare well compared to other drugs.
The FDA recommends the characterization of in vitro selected immune viruses to determine the particular antiviral method of action for the antiviral product creation.
Data proposed that molecular overseeing of the F-motif of the polymerase in COVID-19 patients treated with remdesivir is also warranted.
Patients With Moderate COVID-19
The current proof on the administering of remdesivir in patients diagnosed with moderate COVID-19 pointing toward a net benefit for remdesivir and proposes that a shorter treatment duration (five days) is as effective as a longer one (10 days) with no increase in side effects (16).
Low-certainty proof suggests that the five-day course may be superior for recovery, mortality, and clinical benefits.
Related Article: COVID-19 Vaccine Could Be Made Available By Year-End, Says WHO
COVID-19 Vaccine Could Be Made Available By Year-End, Says WHO